MapLight Therapeutics officer plans $576K share sale
The proposed shares are to be sold solely to satisfy tax withholding obligations connected with restricted stock unit vesting.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. officer Christopher A. Kroeger reported an intended sale of 73,691 common shares for an aggregate market value of $575,526.71, with an approximate sale date of October 15, 2026. The notice also lists prior sales by Christopher Kroeger of 61,778 shares on July 15, 69,082 shares on July 16 and 16,779 shares on July 17, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Unit Grant financial
tax withholding obligations financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.